Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
about
Targeting SRC in mucinous ovarian carcinoma.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Mucinous tumors of the ovary: current thoughts on diagnosis and managementUnmasking the complexities of mucinous ovarian carcinoma.High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) RiskCyclin D1 predicts the prognosis of advanced serous ovarian cancerComparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.Targeting SRC and tubulin in mucinous ovarian carcinoma.Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer.Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study.Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator.The miR-200 family in ovarian cancer.Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.What is the accuracy of frozen section in the diagnosis of mucinous ovarian tumours? A 9-year review of performance in a Greek tertiary referral centre.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).A Metastatic Gastric Tumor from Ovarian Cancer.Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma.Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.Recent Insights into Mucinous Ovarian Carcinoma.
P2860
Q33638051-F7599483-77AD-46D9-B30B-6BCA72F20DB0Q33735170-AE848828-3C00-49C5-A688-1E0EC108A796Q34175056-131BA5DE-FB5F-4D50-9F32-0F53EB88EC88Q34389383-51851E05-D454-4508-9BF7-6222533221F3Q34528724-E32402CD-DDE0-4DDD-BEDF-4DF960890B0AQ34616645-FA4BC862-BEAD-4883-BF3A-93EA163E7DABQ34667838-6F745358-0A33-4B27-B8B2-7015D8724CEAQ34695404-BAA0605D-C004-4207-AE40-8580B7F08F89Q35098369-5A88B5D3-D3A4-4574-83FC-B6297DE75B49Q35668946-EE6BC709-08CE-4A8D-BCBA-58D293C6B79CQ36230481-0C6E6451-9DA9-4FEA-9EF0-EAB2AF2FA93CQ36817504-8DD70E99-F9C9-4097-82B4-9B779BA4CD36Q37366157-917006C9-0BD4-42BA-9522-7784E9EE734AQ38080036-2F4D6FD4-E782-4C6D-81F9-0547454DFA11Q38382139-0ED03379-6032-4351-9CCE-B61B529F031CQ39176734-C12037F6-0632-4264-8B86-3E977BEA8E44Q41390229-0AEFD6C5-0040-425F-AA1E-4E24665AC078Q42371676-F4560526-D085-436A-AC77-FD08B9E29969Q46483826-E7608978-F43F-42E3-85A7-90F2D53337F8Q48371169-E38FE165-4EDF-4862-8C40-CF8464E1A7E5Q48617362-A8029D0A-1297-4E09-9CBD-42343B6F3E96Q50327498-1A4932A0-6BB6-4A76-AFEE-50E33418A5DBQ51817178-30F03EE6-D77C-401F-A390-BE3F6470EFCCQ52723773-C7AC011E-A938-4823-88E7-B35C641078A8Q52991385-6819650B-805A-4FAF-A3D3-BCF4EDE1AC92Q54386228-B9D4159F-F072-4DCD-94F0-D961048F525AQ55056786-34DA8A0B-0996-4DF5-9E86-813CCC74C9A4Q55163731-3A741DD9-8BC6-45D7-9F8F-97F21190D9E6Q55609057-6C3DF07E-E255-4DAE-B98A-EF4E7BC4CBE5
P2860
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@en
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@nl
type
label
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@en
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@nl
prefLabel
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@en
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@nl
P2093
P1433
P1476
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
@en
P2093
Junzo Kigawa
Makoto Yasuda
Masamichi Hiura
Mitsuaki Suzuki
Muneaki Shimada
Ryuichiro Nishimura
Toru Sugiyama
Tsunehisa Kaku
Tsutomu Tabata
Yoshihiro Ohishi
P304
P356
10.1016/J.YGYNO.2009.02.010
P407
P577
2009-03-10T00:00:00Z